Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences RNAi & miRNA

Mark Behlke's Biography

Mark Behlke, Vice President/Chief Scientific Officer, Integrated DNA Technologies Inc

As the Chief Scientific Officer, Dr. Behlke has directed research activities at IDT since joining the company in 1995 with a focus on novel molecular biology applications of oligonucleotide-based technologies. In addition, Dr. Behlke (together with Dr. John Rossi, from the Beckman Research Institute at the City of Hope) is a scientific co-founder of Dicerna Pharmaceuticals, located in Boston, Massachusetts and is a member of the Dicerna Scientific Advisory Board.
Before joining IDT, Dr. Behlke was a Physician Postdoctoral Fellow of the Howard Hughes Medical Institute at the Whitehead Institute for Biomedical Research, MIT, where he studied human sex determination in the laboratory of Dr. David Page. He was a Resident Physician in Internal Medicine and Fellow in Endocrinology at Brigham and Women’s Hospital, Boston. Dr. Behlke received his M.D. and Ph.D. degrees from Washington University, St. Louis in 1988, where he studied immunogenetics in the laboratory of Dr. Dennis Loh. He received his B.S. degree from the Massachusetts Institute of Technology in 1981.
Mark A. Behlke is an inventor on over 30 issued US patents, has numerous pending patent applications, and is an author on over 100 scientific publications and book chapters. He is an internationally recognized expert in nucleic acid technologies and is on the editorial board of leading journals in the field, including Molecular Therapy, Molecular Therapy - Nucleic Acids, and Nucleic Acid Therapeutics.

Mark Behlke Image

Improved Design of Anti-miRNA Oligonucleotides

Friday, 20 April 2012 at 11:45

Add to Calendar ▼2012-04-20 11:45:002012-04-20 12:45:00Europe/LondonImproved Design of Anti-miRNA

Anti-miRNA Oligonucleotides (AMOs) are a version of antisense oligos that inhibit miRNA function by a steric blocking mechanism of action. IDT has developed a novel chemical modifying group which improves nuclease stability and increases potency while maintaining high specificity of 2’OMe AMOs.

Add to Calendar ▼2012-04-19 00:00:002012-04-20 00:00:00Europe/LondonRNAi and